The HyperArc registry collects real-world patient data to improve HyperArc radiosurgery techniques and expand treatment options for patients
Icon Group will participate in the Varian-sponsored HyperArc registry. (Credit: fernando zhiminaicela from Pixabay)
Australia-based cancer care provider Icon Group will participate in the Varian-sponsored HyperArc registry, designed to collect patient data to inform and expand treatment options for patients with brain tumours.
Varian, which is a Siemens Healthineers company, said that the HyperArc technology enables clinicians to use radiation treatment with highly conformal dosages to treat tumours. The automated technology is said to be capable of targeting several tumours in different locations in the brain.
The HyperArc registry will store data gathered during and following the course of radiation therapy by utilising HyperArc on a Varian linear accelerator. It also enables doctors to assess caseloads, procedures, and treatment approach outcomes while also understanding real-world HyperArc usage scenarios.
To facilitate clinical research, an automated method uploads treatment data to the registry, said Varian.
Radiation oncologist and principal investigator Matthew Foote said: “We have already started to see the potential of HyperArc to greatly improve quality of life for patients with multiple brain tumours.
“Previously many of these patients would have had to receive radiation to the whole brain, resulting in undesirable side effects and suboptimal quality of life. Now we can treat up to 20 metastases in one treatment session, with promising results.
“The registry is another step forward in our ability to analyse real world data to inform treatment pathway decisions and ultimately push the boundaries of this technology to improve patient outcomes and evolve how we treat cancer.”
Varian added that the registry will be accessible at various Icon Cancer Centre sites in Australia with the possibility to spread across the latter’s global network. This multicentre approach will gather anonymised data to assess the relative toxicity, comparative efficacy, and level of care in a sizable patient population, said the Siemens Healthineers company.
The HyperArc registry will make it possible for Icon to work with other organisations like the University of Alabama at Birmingham, which is said to be another significant partner of the registry.